Details
Stereochemistry | ACHIRAL |
Molecular Formula | C44H50N6O2 |
Molecular Weight | 694.9068 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 2 |
SHOW SMILES / InChI
SMILES
C[N+](C)(C)CCCOC1=CC=C(C=C1)C2=C3C=CC(C=C4NC(C=C4)=C(C5=NC(C=C5)=CC6=CC=C2N6)C7=CC=C(OCCC[N+](C)(C)C)C=C7)=N3
InChI
InChIKey=KZTXNPVFWHWJSH-OPFFBBNOSA-N
InChI=1S/C44H50N6O2/c1-49(2,3)25-7-27-51-37-17-9-31(10-18-37)43-39-21-13-33(45-39)29-35-15-23-41(47-35)44(42-24-16-36(48-42)30-34-14-22-40(43)46-34)32-11-19-38(20-12-32)52-28-8-26-50(4,5)6/h9-24,29-30,45,48H,7-8,25-28H2,1-6H3/q+2/b33-29-,34-30-,35-29-,36-30-,43-39-,43-40-,44-41-,44-42-
Molecular Formula | C44H52N6O2 |
Molecular Weight | 696.9227 |
Charge | 2 |
Count |
|
Stereochemistry | MIXED |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Exeporfinium (XF-73), a dicationic porphyrin derivative, is an antibacterial drug. Exeporfinium acts via a bacterial cell-surface mechanism that affects membrane permeability and integrity, leading to release of intracellular components and bacterial cell death, without lysis. Exeporfinium represents a broad-spectrum Gram-positive antibacterial drug. It also has activity against a number of Gram-negative bacteria. Exeporfinium has been granted Fast Track designation by the US FDA for the prevention of post-surgical staphylococcal infections such as Methicillin Resistant Staphylococcus aureus.
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
[XF-73 - a new antibacterial lead compound]. | 2010 Sep |
|
Investigation of the potential for mutational resistance to XF-73, retapamulin, mupirocin, fusidic acid, daptomycin, and vancomycin in methicillin-resistant Staphylococcus aureus isolates during a 55-passage study. | 2011 Mar |
|
Fungicidal photodynamic effect of a twofold positively charged porphyrin against Candida albicans planktonic cells and biofilms. | 2013 Jun |
Patents
Sample Use Guides
Phase 2 study: 0.3 mL applications in each naris of 0.2% w/w exeporfinium (XF-73) nasal gel for a cumulative dose of 6.0 mg of XF-73.
Route of Administration:
Nasal
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20346634
XF-73 was active [minimum inhibitory concentration (MIC) 0.25-4 mg/L] against all of the Gram-positive bacteria tested, irrespective of the antibiotic resistance profile of the isolates, suggesting that the mechanism of action of XF-73 is unique compared with the major antibiotic classes. Gram-negative activity was lower (MIC 1 mg/L to > 64 mg/L).
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 05:13:13 GMT 2023
by
admin
on
Sat Dec 16 05:13:13 GMT 2023
|
Record UNII |
R41ECT47G6
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
R41ECT47G6
Created by
admin on Sat Dec 16 05:13:14 GMT 2023 , Edited by admin on Sat Dec 16 05:13:14 GMT 2023
|
PRIMARY | |||
|
9918583
Created by
admin on Sat Dec 16 05:13:14 GMT 2023 , Edited by admin on Sat Dec 16 05:13:14 GMT 2023
|
PRIMARY | |||
|
756818-36-7
Created by
admin on Sat Dec 16 05:13:14 GMT 2023 , Edited by admin on Sat Dec 16 05:13:14 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET ORGANISM->INHIBITOR |
|
||
|
TARGET ORGANISM->INHIBITOR |
|
||
|
TARGET ORGANISM->INHIBITOR |
|
||
|
TARGET ORGANISM->INHIBITOR |
|
||
|
TARGET ORGANISM->INHIBITOR |
|
||
|
TARGET ORGANISM->INHIBITOR |
|
||
|
TARGET ORGANISM->INHIBITOR |
|
||
|
TARGET ORGANISM->INHIBITOR |
|
||
|
TARGET ORGANISM->INHIBITOR |
|
||
|
TARGET ORGANISM->INHIBITOR |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|